TNBC - Triple-Negative Breast Cancer Clinical Trials

17 studies are recruiting for tnbc - triple-negative breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

2. Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

   For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are …

   Stage

   Not phased

   Ages

   18 to 99

   Site

   Birmingham Hematology Associates, Birmingham, Alabama

   Locations

   16 in total

   Run by

   Tempus AI

   See if you can join NCT07211178 on ClinicalTrials.gov

3. Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

   This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer. The trial is designed to test the safety and efficacy of adding ivonescimab in patients with early TNBC undergoing neoadjuvant ch…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   4 in total

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT07017673 on ClinicalTrials.gov

4. Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

   This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mercy Hospital - FTS, Fort Smith, Arkansas

   Locations

   8 in total

   Run by

   Elephas

   See if you can join NCT07327489 on ClinicalTrials.gov

5. BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

   This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale New Haven Hospital, New Haven, Connecticut

   Locations

   17 in total

   Run by

   SillaJen, Inc.

   See if you can join NCT05768932 on ClinicalTrials.gov

6. Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

   This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast cancer, who have not responded to previous treatments. Part…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   National Institute of Health Clinical Center, Bethesda, Maryland

   Locations

   3 in total

   Run by

   The Methodist Hospital Research Institute

   See if you can join NCT05660083 on ClinicalTrials.gov

7. Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

   Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC). Primary Objective: To assess the safety of neoadjuvant dupilumab and pembrolizumab plus weekly paclitaxel and carboplatin as measured by th…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Mount Sinai Health System, New York, New York

   Run by

   Rima Patel

   See if you can join NCT06637306 on ClinicalTrials.gov

8. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov

9. Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

   This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients with high-risk TNBC. The primary objective is to assess the pathologic complete response (pCR) rate where pCR is defined as the absence of i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Stephen Shiao

   See if you can join NCT05491226 on ClinicalTrials.gov

10. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dothan Hematology & Oncology, Dothan, Alabama

    Locations

    4 in total

    Run by

    Radiopharm Theranostics, Ltd

    See if you can join NCT07189871 on ClinicalTrials.gov

11. A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

    The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04683679 on ClinicalTrials.gov

12. NearWave Optical Molecular Monitoring

    The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana

    Run by

    Indiana University

    See if you can join NCT06744465 on ClinicalTrials.gov

13. Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

    The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Stony Brook Breast Center, Stony Brook, New York

    Run by

    Alison Stopeck

    See if you can join NCT06220214 on ClinicalTrials.gov

14. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

15. Role of the Immune Environment in Response to Therapy in Breast Cancer

    This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Abramson Cancer Center, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT05396612 on ClinicalTrials.gov

16. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

    This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Arizona Oncology Associates, Tucson, Arizona

    Locations

    13 in total

    Run by

    Processa Pharmaceuticals

    See if you can join NCT06568692 on ClinicalTrials.gov

17. CtDNA Based MRD Testing for NAC Monitoring in TNBC

    A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Arizona Oncology, Tucson, Arizona

    Locations

    14 in total

    Run by

    Personalis Inc.

    See if you can join NCT06230185 on ClinicalTrials.gov